| Summary: | Background. The presence of large platelets in the pulmonary vessels was first
reported by Aschoff as early as 1893. Somewhat later it was discovered that up to half of
the entire blood platelet pool could be formed by thrombopoietic cells deposited in the
pulmonary capillaries. Because of the nature of the cytokine storm in COVID-19, pulmonary
platelets may play a significant role in the development of fatal thromboembolic complications.
In addition, there are a large number of clinical conditions in which large platelets
are also found. Young large platelets contain a large number of granules with cytokines
such as RANTES, IL-1β, etc., which contribute to the release of other pro-inflammatory cytokines
that stimulate even more platelet synthesis. The purpose of the study is to compare
changes in platelet indices in patients who died and died from coronavirus infection. Materials
and methods. 149 results of platelet indices of the general blood count were analysed
in 94 patients with identified coronavirus infection. The results were divided into 3 groups:
those who died of COVID-19, those who did not die of COVID-19 of the same, older age
and those who did not die of COVID-19 of younger age. The following platelet indices
were considered: PLT, MPV, PDW, P-LCR. Results and conclusions. The deceased patients
(70,6 ± 11,4 years old) had lower platelet count (p<0,01) and higher PDW, P-LCR
indices (p<0,05) compared to the patients who didn't die from COVID-19, which indicates
both percentage and absolute increase of the large platelet fraction. In the study, we looked
at changes in several platelet indices: PLT, MPV, PDW, P-LCR in patients with COVID-
19. Deceased patients (70.6 ± 11.4 years) showed decreased platelet count (p<0.01) and increased
PDW, P-LCR indices, compared to patients who did not die from COVID-19.
Conclusions. The presence of macrothrombocytes in deceased patients indicates their increase
over time, providing an opportunity for its timely screening and predicting the development
of thromboembolic complications pro COVID-19.
|
|---|